United States Patent 9,181,549: A Detailed Analysis of Scope and Claims
Introduction
United States Patent 9,181,549, assigned to Ionis Pharmaceuticals Inc., is a significant patent in the field of pharmaceuticals, particularly focusing on conjugated antisense compounds and their applications. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.
Patent Overview
Title and Assignees
The patent, titled "Conjugated Antisense Compounds and Their Use," is assigned to Ionis Pharmaceuticals Inc. This indicates that Ionis Pharmaceuticals holds the intellectual property rights for the inventions described in the patent[5].
Priority Date and Grant Date
The priority date for this patent is May 1, 2013, which marks the earliest date when the inventors filed a patent application that is part of the current patent's family. The patent was granted on November 10, 2015[5].
Scope of the Patent
Invention Description
The patent describes conjugated antisense compounds, which are designed to target and modulate the expression of specific genes. These compounds are conjugated with various moieties to enhance their delivery, stability, and efficacy. The invention includes methods for preparing these compounds and their use in treating various diseases, such as those related to genetic disorders or viral infections[5].
Technical Field
The technical field of this patent is in the area of antisense oligonucleotides, which are short, single-stranded nucleic acids designed to bind to specific mRNA sequences. This binding can prevent the translation of the target gene, thereby modulating gene expression. The conjugation aspect is crucial as it improves the pharmacokinetic and pharmacodynamic properties of the antisense compounds[5].
Claims Analysis
Independent and Dependent Claims
The patent includes a set of independent and dependent claims that define the scope of the invention. Independent claims typically describe the broadest aspects of the invention, while dependent claims narrow down the scope by adding additional features or limitations.
- Independent Claims: These claims define the core aspects of the conjugated antisense compounds, including their structure, the type of conjugates used, and the methods for their preparation and use.
- Dependent Claims: These claims build upon the independent claims by specifying particular types of conjugates, target genes, or methods of administration. For example, a dependent claim might specify a particular disease that the compound is used to treat[5].
Claim Coverage Matrix
To understand the full scope of the patent, a Claim Coverage Matrix can be useful. This matrix categorizes the claims by their scope concepts, helping to identify which patents and claims are actively protecting the intellectual property. It also highlights gaps or opportunities in the current claim coverage[3].
Patent Landscape
Related Patents and Applications
The patent landscape for antisense compounds is complex and involves numerous patents and applications from various companies. Ionis Pharmaceuticals, in particular, has a significant portfolio of patents related to antisense technology.
- Patent Family: The patent 9,181,549 is part of a larger patent family that includes other related patents and applications filed in different jurisdictions. Using tools like the Global Dossier or the Common Citation Document (CCD), one can view the patent family and related applications filed at participating IP Offices[1].
Competitors and Collaborations
The field of antisense compounds is highly competitive, with several companies, including Biogen and Bayer, collaborating with Ionis Pharmaceuticals on various projects. These collaborations often involve licensing agreements and joint development of new therapies, which can impact the patent landscape[4].
International Patent Search
To ensure that the invention is novel and non-obvious globally, it is essential to conduct an international patent search. Databases such as the European Patent Office's esp@cenet, the Japan Patent Office, and the World Intellectual Property Organization's PATENTSCOPE can be used to search for similar patents and applications in other countries[1].
Patent Analytics and Claim Charts
Patent analytics tools, such as those provided by Schwegman, can help in categorizing and analyzing the claims of the patent. These tools generate interactive claim charts that make it easier to review patent coverage with engineers, scientists, and management. This helps in identifying gaps in current coverage and highlighting future design opportunities[3].
Expiration and Generic Entry
The expiration date of the patent is crucial for understanding when generic versions of the conjugated antisense compounds can enter the market. Patent 9,181,549 is set to expire on November 10, 2035, assuming no extensions or adjustments. After this date, generic manufacturers can seek approval to produce and market similar compounds[2].
Key Takeaways
- Patent Scope: The patent covers conjugated antisense compounds, their preparation, and their use in treating various diseases.
- Claims Analysis: The patent includes independent and dependent claims that define the scope of the invention.
- Patent Landscape: The patent is part of a larger family and is influenced by collaborations and licensing agreements with other companies.
- International Search: Conducting an international patent search is essential to ensure the novelty and non-obviousness of the invention globally.
- Patent Analytics: Tools like Claim Coverage Matrix and claim charts are useful for analyzing and managing the patent portfolio.
FAQs
What is the main invention described in United States Patent 9,181,549?
The main invention described in United States Patent 9,181,549 is conjugated antisense compounds and their use in treating various diseases by modulating gene expression.
Who is the assignee of this patent?
The assignee of this patent is Ionis Pharmaceuticals Inc.
What is the priority date for this patent?
The priority date for this patent is May 1, 2013.
How can one analyze the claims of this patent effectively?
One can use patent analytics tools to categorize and analyze the claims, generating interactive claim charts to identify gaps and opportunities in the current coverage.
When is the patent set to expire?
The patent is set to expire on November 10, 2035, assuming no extensions or adjustments.
What databases can be used to conduct an international patent search?
Databases such as the European Patent Office's esp@cenet, the Japan Patent Office, and the World Intellectual Property Organization's PATENTSCOPE can be used to conduct an international patent search.
Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- DrugPatentWatch - Patent 9181549: https://www.drugpatentwatch.com/p/patent/9181549
- SLWIP - Patent Analytics: https://www.slwip.com/services/patent-analytics/
- Ionis Pharmaceuticals - SEC Filing: https://ir.ionispharma.com/static-files/ceec4c5b-061d-4301-adc3-a34487088dd6
- Unified Patents - WO-2011005861-A9: https://portal.unifiedpatents.com/patents/patent/WO-2011005861-A9
